Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.52 |
| ▸ | TNF | P01375 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.42 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4728366 | 0.87 | HDAC6 (0.59) | HDAC6TNFMAPK1TSHRHDAC3 | |
| SCHEMBL13720566 | 0.81 | SRC (0.56) | EHMT2EHMT1KDM4E | |
| SCHEMBL4873272 | 0.81 | HDAC6 (0.68) | HDAC6TNFMAPK1TSHRHDAC3 | |
| SCHEMBL4865189 | 0.80 | TNF (0.67) | HDAC6TNFMAPK1TSHRHDAC3 | |
| SCHEMBL15680310 | 0.80 | HDAC6 (0.70) | HDAC6TNFMAPK1TSHRHDAC3 | |
| SCHEMBL19645656 | 0.79 | ELANE (0.53) | HDAC6ALDH1A1KDM4E | |
| SCHEMBL24165356 | 0.77 | HDAC6 (0.49) | HDAC6TNFMAPK1TSHRHDAC3 | |
| SCHEMBL23959931 | 0.77 | HDAC6 (0.56) | HDAC6TNFMAPK1TSHRHDAC3 | |
| SCHEMBL19645657 | 0.77 | HDAC6 (0.56) | HDAC6TNFMAPK1TSHRHDAC3 | |
| SCHEMBL5562061 | 0.77 | HDAC6 (0.55) | HDAC6TNFMAPK1TSHRHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713323-B2 | Crystalline forms of therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20210355133-A1 | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-20190077810-A1 | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2019-03-14 | — | — | US | disclosed |
| US-9827248-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713323-B2 | Crystalline forms of therapeutic compounds and uses thereof | AQP3, CFTR, NPC1 | HDAC6 63/4885TNF 874/4885MAPK1 3907/4885 |
| US-20210355133-A1 | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF | AQP3, CFTR, NPC1 | HDAC6 63/4885TNF 874/4885MAPK1 3907/4885 |
| US-20190077810-A1 | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF | AQP3, CFTR, NPC1 | HDAC6 63/4885TNF 874/4885MAPK1 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.